Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jad Chahoud"'
Publikováno v:
Mayo Clinic Proceedings. 96:720-732
Penile squamous cell carcinoma (PSCC) is a rare cancer, with approximately 2000 new cases in the United States and 35,000 globally every year. Multiple risk factors are involved in PSCC, but most importantly, the high-risk human papillomavirus infect
Autor:
Jingsong Zhang, Logan Zemp, Scott M. Gilbert, Ali Hajiran, Wade J. Sexton, Rohit Jain, Roger Li, Nicholas H. Chakiryan, Lee A. Hugar, Brandon J. Manley, Jad Chahoud, Da David Jiang, Elizabeth Green, Kyle A. Gillis
Publikováno v:
Urologic oncology. 40(3)
Clinical trials have not shown a significant overall survival (OS) difference between chemotherapy and immunotherapy as first-line agents in metastatic urothelial carcinoma (UC). However, the generalizability of these findings in a real-world setting
Autor:
Guru Sonpavde, Andrew Lai, Mounsif Azizi, Lance C. Pagliaro, Andrea Necchi, Ahmet M. Aydin, Charles C. Peyton, Jad Chahoud, Philippe E. Spiess, Ali Hajiran, Ambuj Kumar, Suks Minhas
Publikováno v:
The Journal of urology. 203(6)
PURPOSE: Neoadjuvant chemotherapy is a recommended treatment for patients with penile cancer with bulky inguinal lymphadenopathy or unresectable primary tumors, although there is no evidence of its benefit from randomized trials. MATERIALS AND METHOD
Most patients with advanced penile cancer will have relapsed disease after cisplatin-based combination chemotherapy. Unfortunately, these patients have dismal outcomes with salvage chemotherapy, surgery, or radiation. In this review we will discuss t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd1f527b599160b4923579c666609afe
Publikováno v:
Current opinion in oncology. 30(3)
Purpose of review In the present review, we summarize the recent developments in the management of germ cell tumors (GCTs). Recent findings Treatment-related acute and late-onset toxicity remains a key challenge in the management of GCTs, with recent
Autor:
Jad, Chahoud, Dawen, Sui, William D, Erwin, Alison M, Gulbis, Martin, Korbling, Mingzhi, Zhang, Sairah, Ahmed, Gheath, Alatrash, Paolo, Anderlini, Stefan O, Ciurea, Betul, Oran, Luis E, Fayad, Roland L, Bassett, Elias J, Jabbour, L Jeffrey, Medeiros, Homer A, Macapinlac, Ken H, Young, Issa F, Khouri
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(10)
PURPOSE: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan ((90)YIT) in patients with relapsed diffuse large B